Proxeon and Bruker Daltonik Announce OEM Agreement
News Nov 16, 2007
Proxeon and Bruker Daltonik have announced that the companies have entered into an OEM agreement. Under the agreement, Bruker Daltonik will sell Proxeon’s nanoscale chromatography system, EASY-nLC™, together with their range of products for mass spectrometry, beginning initially in the Europe region.
“Combining our range of proteomics MS products with the novel nanoLC system from Proxeon takes proteomics analysis to a new level in terms of performance, reliability and ease-of-use, answering the increasing demand for integrated solutions,” said Dr. Alexander Harder; Director of Product Management of Bruker Daltonik.
EASY-nLC is a fully integrated, split-free nanoscale LC system, optimized for use with mass spectrometry and in particular LC-MS applications in proteomics. The product is already in use in proteomics laboratories and will also continue to be sold through the Proxeon sales team.
Bruker Daltonics offers a well-established range of mass spectrometry systems and solutions that are widely used in proteomics research, including their HCTultra™ ion trap, micrOTOF-Q™, and apex ultra™ instrument series. The Easy-nLC and MS systems are already completely integrated via Bruker Compass™ software, offering productivity advantages for proteomics researchers. The combined system will be sold by Bruker Daltonik through their sales and marketing organization.
Arrow Poison Potential Male Birth ControlNews
Women have many options for oral contraceptives that are safe, effective and reversible, but despite decades of research, men have none. Now, scientists report a rat study that shows they finally have a good lead for a male birth control pill. It's based on ouabain, a plant extract that African warriors and hunters traditionally used as a heart-stopping poison on their arrows.READ MORE
Robust Multiplex Mass Spectrometric Assay for Screening Small-Molecule InhibitorsNews
A new original research article presents a fast, sensitive, and robust methodology for screening small molecule inhibitors against CD73/Ecto-5'-Nucleotidase, a promising target for developing anti-cancer drugs.READ MORE